Immutep (ASX:IMM) Other Long-Term Liabilities: A$0.03 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Immutep Other Long-Term Liabilities?

Immutep ASX:IMM Other Long-Term Liabilities is A$0.03 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Immutep's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.03 Mil.

Immutep's quarterly other long-term liabilities declined from Jun. 2025 (A$0.01 Mil) to Sep. 2025 (A$0.00 Mil) but then increased from Sep. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.03 Mil).

Immutep's annual other long-term liabilities increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.01 Mil) but then declined from Jun. 2024 (A$0.01 Mil) to Jun. 2025 (A$0.01 Mil).

Immutep Other Long-Term Liabilities Related Terms

Immutep Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Immutep's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep Other Long-Term Liabilities Chart

Immutep Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.72 0.00 0.00 0.01 0.01

Immutep Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.00 0.03 0.00

Immutep Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.03 Mil mean?
Immutep (ASX:IMM) has a Other Long-Term Liabilities of A$0.03 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Immutep and its competitors.
Is Immutep's Other Long-Term Liabilities too high?
Immutep's current Other Long-Term Liabilities is A$0.03 Mil.
How does Immutep's Other Long-Term Liabilities compare to VRTX and REGN?
Immutep's Other Long-Term Liabilities of A$0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Immutep and its competitors. Immutep's current Other Long-Term Liabilities is A$0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (ASX:IMM) has a current Other Long-Term Liabilities of A$0.03 Mil. The current Other Long-Term Liabilities is A$0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Immutep (ASX:IMM), the current Other Long-Term Liabilities is A$0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.